Stockwatch: The Rehabilitation Of AstraZeneca
This article was originally published in Scrip
Last Friday was triple witching. This last hour of the US stock market on the third Friday of December (also March, June and September) is associated with significant volatility as the index futures and options and stock options all expire at the same time and are settled.
You may also be interested in...
Biogen’s poor third-quarter results cannot be blamed solely on the pandemic. Pipeline attrition and underperformance in most franchises pushes all the risk onto a dubious throw of the regulatory dice.
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.